

Supplementary Table 1. Adjusted association between *MTHFR* rs1801133 polymorphism and liver fibrosis/cirrhosis progression in HCV-infected patients.

A) <u>Ratio LSM2/LSM1</u>	aAMR	95% CI		p-value
		Low	up	
Additive				
<i>MTHFR</i> rs1801133 (G)	0.90	0.83	0.98	0.020
Gender (male)	1.16	1.03	1.30	0.015
Age (years)	1.00	1.00	1.01	0.136
High alcohol intake	1.17	0.98	1.38	0.079
Baseline LSM (kPa)	0.94	0.91	0.96	<0.001
HCV therapy during follow-up *	1.21	1.07	1.37	0.002
<i>MERTK</i> rs4374383 (G)	1.12	1.02	1.22	0.012
<i>IL7RA</i> rs6897932 (T)	1.16	1.05	1.28	0.005
<i>DARC</i> rs12075 (G)	0.92	0.85	1.00	0.047
<i>PNPLA3</i> rs738409 (G)	1.11	1.02	1.21	0.020
Dominant				
<i>MTHFR</i> rs1801133 (AG/GG)	0.80	0.68	0.95	0.009
Gender (male)	1.16	1.03	1.30	0.011
Age (years)	1.00	1.00	1.01	0.137
High alcohol intake	1.21	1.02	1.44	0.028
Baseline LSM (kPa)	0.94	0.91	0.97	<0.001
Time of follow-up (months)	1.00	1.00	1.01	0.177
HCV therapy during follow-up *	1.23	1.09	1.38	0.001
<i>MERTK</i> rs4374383 (G)	1.13	1.03	1.23	0.007
<i>IL7RA</i> rs6897932 (T)	1.15	1.04	1.28	0.005
<i>DARC</i> rs12075 (G)	0.93	0.85	1.00	0.064
<i>PNPLA3</i> rs738409 (G)	1.12	1.03	1.23	0.010
B) <u>Cirrhosis progression (F4)</u>				
Additive	aOR	95% CI		p-value
		Low	up	
<i>MTHFR</i> rs1801133 (G)	0.43	0.19	0.95	0.038
Gender (male)	3.10	1.01	9.53	0.048
Age (years)	1.06	1.00	1.12	0.040
Baseline LSM (kPa)	1.72	1.30	2.27	<0.001
HCV therapy during follow-up *	3.46	1.20	10.01	0.022
<i>MERTK</i> rs4374383 (G)	2.28	0.96	5.45	0.063
<i>DARC</i> rs12075 (G)	0.46	0.20	1.06	0.067
<i>PNPLA3</i> rs738409 (G)	2.55	1.13	5.72	0.024
Dominant				
<i>MTHFR</i> rs1801133 (AG/GG)	0.21	0.06	0.74	0.015
Gender (male)	3.04	0.99	9.38	0.053
Age (years)	1.06	1.00	1.13	0.039
Baseline LSM (kPa)	1.72	1.30	2.27	<0.001
HCV therapy during follow-up *	3.40	1.16	9.97	0.025
<i>MERTK</i> rs4374383 (G)	2.34	0.93	5.91	0.071

<i>IL7RA</i> rs6897932 (T)	1.81	0.73	4.46	0.199
<i>DARC</i> rs12075 (G)	0.51	0.22	1.20	0.122
<i>PNPLA3</i> rs738409 (G)	2.69	1.16	6.25	0.021

(*), Only patients who failed therapy were included.

Statistics: data were calculated by multivariate regression adjusted by the most important clinical and epidemiological characteristics (see **statistical analysis** section). Significant differences are shown in bold.

Abbreviations: aAMR, adjusted arithmetic mean ratio; aOR, adjusted odds ratio; 95%CI, 95% confidence interval; p-value, level of significance; LSM, liver stiffness measure; kPa, F4, cirrhosis; MTHFR, methylenetetrahydrofolate reductase.